摘要
目的:探讨孟鲁司特钠咀嚼片口服联合双嘧达莫片对呼吸道合胞病毒(RSV)感染毛细支气管炎患儿血清炎症因子水平及炎症免疫状态的影响。方法:按照随机数字表法将本院2017年4月—2019年7月期间收治的105例RSV感染毛细支气管炎患儿分组,对照组52例给予双嘧达莫片口服25 mg/次,3次/d;观察组在对照组基础上增加孟鲁司特钠咀嚼片,年龄6个月以下者2.5 mg/次,年龄6个月以上者5.0 mg/次,1次/d,睡前口服,连续治疗4周。观察两组患儿临床疗效、症状改善时间、炎症因子水平、免疫状态及药物不良反应。结果:治疗后,观察组总有效率(94.34%)较对照组(76.92%)高(P<0.05);观察组咳嗽咳痰、喘息及肺部哮鸣音改善时间均较对照组短(P<0.05);治疗前,两组白介素-5(IL-5)、白介素-17(IL-17)、白介素-4(IL-4)及肿瘤坏死因子-α(TNF-α)水平比较差异无统计学意义(P>0.05),治疗后,两组IL-5、IL-17、IL-4及TNF-α水平均降低(P<0.05),观察组较对照组降低明显(P<0.05);治疗前,两组特异性免疫球蛋白E(sIgE)、总免疫球蛋白E(tIgE)、免疫球蛋白G(IgG)及免疫球蛋白A(IgA)水平比较差异无统计学意义(P>0.05),治疗后两组sIgE、tIgE、IgG及IgA水平均降低(P<0.05),观察组较对照组降低明显(P<0.05);两组患儿不良反应比较差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合双嘧达莫片治疗RSV毛细支气管炎患儿可通过抑制炎症反应,调节免疫功能,进而提高临床疗效,缩短症状缓解时间且不良反应较少。
Objective:To investigate the effects of montelukast sodium chewable tablets combined with dipyridamole tablets on serum inflammatory factor levels and inflammatory immune status in children with respiratory syncytial virus(RSV)infection with bronchiolitis.Methods:According to the random number table method,105 children with RSV infection with bronchiolitis admitted to our hospital from April 2017 to July 2019 were divided into groups.In the control group,52 patients were given dipyridamole tablets(25 mg/time,3 times/day).The observation group(53 patients)were additively given montelukast sodium chewable tablets,2.5 mg/time for those younger than 6 months,and 5.0 mg/time for those older than 6 months,once a day,orally before going to bed for 4 weeks.Clinical efficacy,symptom improvement time,inflammatory cytokines level,immune status,and adverse reactions were observed in both groups.Results:After treatment,the total effective rate of the observation group(94.34%)was higher than that of the control group(76.92%)(P<0.05).The improvement time of cough,sputum,wheezing,and lung wheezing in the observation group was shorter than that in the control group(P<0.05).Before treatment,there were no significant differences in the levels of IL-5,IL-17,IL-4,and TNF-αbetween the two groups(P>0.05).After treatment,the levels of IL-5,IL-17,IL-4 and TNF-αin the two groups were decreased,and those in the observation group were significantly lower than those in the control group(P<0.05).Before treatment,there were no significant differences in sIgE,tIgE,IgG,and IgA levels between the two groups(P>0.05).After treatment,the levels of sIgE,tIgE,IgG and IgA in the two groups were all decreased,and the decrease was significantly in the observation group compared with the control group(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Montelukast sodium combined with dipyridamole tablet in the treatment of children with RSV bronchiolitis can inhibit the inflammatory r
作者
刘曼丽
周卫东
Liu Manli;Zhou Weidong(Zhoukou Hospital of Traditional Chinese Medicine,Henan 466000)
出处
《天津药学》
2021年第2期51-54,共4页
Tianjin Pharmacy
